A serious adverse event is an untoward medical occurrence during a clinical trial or after product exposure that results in death, is life-threatening, requires inpatient hospitalization or prolongation, causes persistent or significant disability/incapacity, or leads to a congenital anomaly. In safety reporting and clinical study reports, SAEs are classified, assessed for causality, and reported to regulators within defined timelines.
In translation and localization, SAE narratives, safety case forms, and expedited reporting templates appear across clinical safety documents. Translators often process investigator-facing case report forms, patient adverse-event narratives, and pharmacovigilance reports for submission in multiple countries. Consistent rendering of MedDRA terms and severity scales is important for regulatory review.
A common error is translating “serious” as “severe” in languages where the terms can overlap; in regulatory English these are not equivalent, because seriousness is a regulatory reporting criterion while severity describes intensity. Under-translating the SAE criteria can cause misclassification, delayed reporting, and rejection of safety submissions.
FDA, CE/MDR and NMPA reviewers assess the submitted wording itself. Regulatory bodies require traceable, accountable translation, and an inconsistent term can delay or fail a submission.
Angel Translation locks terms like this into a project terminology base before expert review begins, so the same source term resolves to the same target term across every document in a submission — and stays consistent in the next revision. See the 8-step AI + expert workflow.
Send us the files. Acknowledged in 4 hours, quoted in 24.
Request a Quote →Life Science solutions →